Australia’s strength in radiopharmaceutical research is running into a patient-access barrier that could undermine investment in trials, manufacturing and future therapies, industry executives warned at the Ausbiotech conference…
Australia’s strength in radiopharmaceutical research is running into a patient-access barrier that could undermine investment in trials, manufacturing and future therapies, industry executives warned at the Ausbiotech conference in Queensland Oct. 21–23.
Source disclosure
This is a source-linked briefing. Read the original report from Bioworld .